181 related articles for article (PubMed ID: 36758419)
21. Proangiogenic tumor proteins as potential predictive or prognostic biomarkers for bevacizumab therapy in metastatic colorectal cancer.
Bruhn MA; Townsend AR; Khoon Lee C; Shivasami A; Price TJ; Wrin J; Arentz G; Tebbutt NC; Hocking C; Cunningham D; Hardingham JE;
Int J Cancer; 2014 Aug; 135(3):731-41. PubMed ID: 24374727
[TBL] [Abstract][Full Text] [Related]
22. Antiangiogenic therapy for high-grade glioma.
Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N
Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542
[TBL] [Abstract][Full Text] [Related]
23. Patients with low nicotinamide N-methyltransferase expression benefit significantly from bevacizumab treatment in ovarian cancer.
Li J; Yue H; Yu H; Lu X; Xue X
BMC Cancer; 2021 Jan; 21(1):67. PubMed ID: 33446144
[TBL] [Abstract][Full Text] [Related]
24. Atezolizumab and Bevacizumab Attenuate Cisplatin Resistant Ovarian Cancer Cells Progression Synergistically via Suppressing Epithelial-Mesenchymal Transition.
Zhang L; Chen Y; Li F; Bao L; Liu W
Front Immunol; 2019; 10():867. PubMed ID: 31105696
[TBL] [Abstract][Full Text] [Related]
25. Are antiangiogenics a good 'partner' for immunotherapy in ovarian cancer?
García-Martínez E; Redondo A; Piulats JM; Rodríguez A; Casado A
Angiogenesis; 2020 Nov; 23(4):543-557. PubMed ID: 32691290
[TBL] [Abstract][Full Text] [Related]
26. MiR-378 as a biomarker for response to anti-angiogenic treatment in ovarian cancer.
Chan JK; Kiet TK; Blansit K; Ramasubbaiah R; Hilton JF; Kapp DS; Matei D
Gynecol Oncol; 2014 Jun; 133(3):568-74. PubMed ID: 24680769
[TBL] [Abstract][Full Text] [Related]
27. Bevacizumab confers significant improvements in survival for ovarian cancer patients with low miR-25 expression and high miR-142 expression.
Li J; Yue H; Li W; Zhu G; Zhu T; Chen R; Lu X
J Ovarian Res; 2021 Nov; 14(1):166. PubMed ID: 34802430
[TBL] [Abstract][Full Text] [Related]
28. Prospective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumab.
Loupakis F; Cremolini C; Yang D; Salvatore L; Zhang W; Wakatsuki T; Bohanes P; Schirripa M; Benhaim L; Lonardi S; Antoniotti C; Aprile G; Graziano F; Ruzzo A; Lucchesi S; Ronzoni M; De Vita F; Tonini G; Falcone A; Lenz HJ
PLoS One; 2013; 8(7):e66774. PubMed ID: 23861747
[TBL] [Abstract][Full Text] [Related]
29. Association of VEGF-A splice variant mRNA expression with outcome in bevacizumab-treated patients with metastatic breast cancer.
Pentheroudakis G; Kotoula V; Kouvatseas G; Charalambous E; Dionysopoulos D; Zagouri F; Koutras A; Papazisis K; Pectasides D; Samantas E; Dimopoulos MA; Papandreou CN; Fountzilas G
Clin Breast Cancer; 2014 Oct; 14(5):330-8. PubMed ID: 24703319
[TBL] [Abstract][Full Text] [Related]
30. VEGF-A levels in bevacizumab-treated breast cancer patients: a systematic review and meta-analysis.
Santos LV; Cruz MR; Lopes Gde L; Lima JP
Breast Cancer Res Treat; 2015 Jun; 151(3):481-9. PubMed ID: 25947646
[TBL] [Abstract][Full Text] [Related]
31. The combination of circulating Ang1 and Tie2 levels predicts progression-free survival advantage in bevacizumab-treated patients with ovarian cancer.
Backen A; Renehan AG; Clamp AR; Berzuini C; Zhou C; Oza A; Bannoo S; Scherer SJ; Banks RE; Dive C; Jayson GC
Clin Cancer Res; 2014 Sep; 20(17):4549-4558. PubMed ID: 24947924
[TBL] [Abstract][Full Text] [Related]
32. Integrating bevacizumab into the management of epithelial ovarian cancer: the controversy of front-line versus recurrent disease.
Monk BJ; Pujade-Lauraine E; Burger RA
Ann Oncol; 2013 Dec; 24 Suppl 10():x53-x58. PubMed ID: 24265406
[TBL] [Abstract][Full Text] [Related]
33. Addition of bevacizumab to chemotherapy in patients with ovarian cancer: a systematic review and meta-analysis of randomized trials.
Li J; Zhou L; Chen X; Ba Y
Clin Transl Oncol; 2015 Sep; 17(9):673-83. PubMed ID: 25990506
[TBL] [Abstract][Full Text] [Related]
34. Anti-angiogenic agents in ovarian cancer: past, present, and future.
Monk BJ; Minion LE; Coleman RL
Ann Oncol; 2016 Apr; 27 Suppl 1(Suppl 1):i33-i39. PubMed ID: 27141068
[TBL] [Abstract][Full Text] [Related]
35. Endothelin-1 genetic polymorphism as predictive marker for bevacizumab in metastatic breast cancer.
Gampenrieder SP; Hufnagl C; Brechelmacher S; Huemer F; Hackl H; Rinnerthaler G; Romeder F; Monzo Fuentes C; Morre P; Hauser-Kronberger C; Mlineritsch B; Greil R
Pharmacogenomics J; 2017 Jul; 17(4):344-350. PubMed ID: 27139155
[TBL] [Abstract][Full Text] [Related]
36. Antiangiogenic therapies in epithelial ovarian cancer.
Teoh DG; Secord AA
Cancer Control; 2011 Jan; 18(1):31-43. PubMed ID: 21273978
[TBL] [Abstract][Full Text] [Related]
37. Blood baseline neutrophil count predicts bevacizumab efficacy in glioblastoma.
Bertaut A; Truntzer C; Madkouri R; Kaderbhai CG; Derangère V; Vincent J; Chauffert B; Aubriot-Lorton MH; Farah W; Mourier KL; Boidot R; Ghiringhelli F
Oncotarget; 2016 Oct; 7(43):70948-70958. PubMed ID: 27487142
[TBL] [Abstract][Full Text] [Related]
38. Pharmacogenetic angiogenesis profiling for first-line Bevacizumab plus oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer.
Gerger A; El-Khoueiry A; Zhang W; Yang D; Singh H; Bohanes P; Ning Y; Winder T; Labonte MJ; Wilson PM; Benhaim L; Paez D; El-Khoueiry R; Absenger G; Lenz HJ
Clin Cancer Res; 2011 Sep; 17(17):5783-92. PubMed ID: 21791631
[TBL] [Abstract][Full Text] [Related]
39. State of the art and up-and-coming angiogenesis inhibitors for ovarian cancer.
Singh N; Badrun D; Ghatage P
Expert Opin Pharmacother; 2020 Sep; 21(13):1579-1590. PubMed ID: 32552175
[TBL] [Abstract][Full Text] [Related]
40. Experience with bevacizumab in the management of epithelial ovarian cancer.
Burger RA
J Clin Oncol; 2007 Jul; 25(20):2902-8. PubMed ID: 17617521
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
